Treatment of Diabetes in Hospitals With Noninsulin Medications Is a Research Priority.
作者信息
Duan Daisy, Mathioudakis Nestoras N, Pilla Scott J
机构信息
Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Division of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
出版信息
Diabetes Care. 2024 Jun 1;47(6):915-917. doi: 10.2337/dci23-0094.
Abstract
摘要
相似文献
1
Treatment of Diabetes in Hospitals With Noninsulin Medications Is a Research Priority.使用非胰岛素药物治疗医院中的糖尿病是一项研究重点。
Diabetes Care. 2024 Jun 1;47(6):915-917. doi: 10.2337/dci23-0094.
2
Insulin and oral agents for managing cystic fibrosis-related diabetes.用于治疗囊性纤维化相关糖尿病的胰岛素和口服药物。
Cochrane Database Syst Rev. 2016 Apr 18;4:CD004730. doi: 10.1002/14651858.CD004730.pub4.
3
Insulin and oral agents for managing cystic fibrosis-related diabetes.用于治疗囊性纤维化相关糖尿病的胰岛素及口服药物。
Cochrane Database Syst Rev. 2013 Jul 26(7):CD004730. doi: 10.1002/14651858.CD004730.pub3.
4
A nomogram to estimate the proportion of patients at hemoglobin A1c target <7% with noninsulin antidiabetic drugs in type 2 diabetes: a systematic review of 137 randomized controlled trials with 39,845 patients.用于评估2型糖尿病患者使用非胰岛素抗糖尿病药物时糖化血红蛋白目标<7%比例的列线图：对137项随机对照试验和39845例患者的系统评价
Acta Diabetol. 2014 Apr;51(2):305-11. doi: 10.1007/s00592-012-0370-9.
5
6
Assessment of medication adherence after enrollment in a health system funded medication assistance program for patients with diabetes.对参加卫生系统资助的糖尿病患者药物援助项目后的用药依从性进行评估。
J Am Pharm Assoc (2003). 2023 Jul-Aug;63(4):1222-1229.e3. doi: 10.1016/j.japh.2023.04.007. Epub 2023 Apr 17.
7
Patient preferences for noninsulin diabetes medications: a systematic review.非胰岛素类糖尿病药物的患者偏好：一项系统综述
Diabetes Care. 2014 Jul;37(7):2055-62. doi: 10.2337/dc13-2527.
8
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.用于治疗糖尿病和慢性肾脏病患者的胰岛素及降糖药物。
Cochrane Database Syst Rev. 2018 Sep 24;9(9):CD011798. doi: 10.1002/14651858.CD011798.pub2.
9
Discontinuation of blood pressure-lowering, glucose-lowering, and lipid-lowering medications after bariatric surgery in patients with morbid obesity: a nationwide cohort study in South Korea.肥胖症患者接受减重手术后停止降压、降糖和调脂药物治疗：韩国全国队列研究。
Surg Obes Relat Dis. 2024 Sep;20(9):840-848. doi: 10.1016/j.soard.2024.03.008. Epub 2024 Mar 15.
10
Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.长效胰岛素类似物甘精胰岛素的系统评价与经济学评估
Health Technol Assess. 2004 Nov;8(45):iii, 1-57. doi: 10.3310/hta8450.
本文引用的文献
1
16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2024.16. 医院中的糖尿病护理：2024 年糖尿病护理标准。
Diabetes Care. 2024 Jan 1;47(Suppl 1):S295-S306. doi: 10.2337/dc24-S016.
2
Association of Continued Use of SGLT2 Inhibitors From the Ambulatory to Inpatient Setting With Hospital Outcomes in Patients With Diabetes: A Nationwide Cohort Study.从门诊到住院环境中持续使用 SGLT2 抑制剂与糖尿病患者住院结局的关联：一项全国性队列研究。
Diabetes Care. 2024 Jun 1;47(6):933-940. doi: 10.2337/dc23-1129.
3
Should glucagon-like peptide-1 receptor agonist treatment be withheld in preoperative management?在术前管理中是否应停用胰高血糖素样肽-1受体激动剂治疗？
J Diabetes. 2023 Sep;15(9):712-713. doi: 10.1111/1753-0407.13469.
4
Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline.非重症监护成人住院患者高血糖管理：内分泌学会临床实践指南。
J Clin Endocrinol Metab. 2022 Jul 14;107(8):2101-2128. doi: 10.1210/clinem/dgac278.
5
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.钠-葡萄糖协同转运蛋白 2 抑制剂恩格列净治疗急性心力衰竭住院患者的多中心随机试验。
Nat Med. 2022 Mar;28(3):568-574. doi: 10.1038/s41591-021-01659-1. Epub 2022 Feb 28.
6
Correction to: Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.对《恩格列净作为附加治疗对因急性失代偿性心力衰竭住院的糖尿病患者充血缓解和肾功能的影响：一项前瞻性随机对照研究》的勘误
Circ Heart Fail. 2021 Apr;14(4):e000067. doi: 10.1161/HHF.0000000000000067. Epub 2021 Apr 20.
7
Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.恩格列净作为附加疗法对因急性失代偿性心力衰竭住院的糖尿病患者的充血和肾功能的影响：一项前瞻性随机对照研究。
Circ Heart Fail. 2021 Mar;14(3):e007048. doi: 10.1161/CIRCHEARTFAILURE.120.007048. Epub 2021 Mar 5.
8
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.索格列净治疗伴有近期恶化心力衰竭的糖尿病患者。
N Engl J Med. 2021 Jan 14;384(2):117-128. doi: 10.1056/NEJMoa2030183. Epub 2020 Nov 16.
9
Perioperative Management of Oral Glucose-lowering Drugs in the Patient with Type 2 Diabetes.2型糖尿病患者口服降糖药的围手术期管理
Anesthesiology. 2020 Aug;133(2):430-438. doi: 10.1097/ALN.0000000000003237.
10
Dulaglutide-combined basal plus correction insulin therapy contributes to ideal glycemic control in non-critical hospitalized patients.度拉鲁肽联合基础胰岛素加校正胰岛素治疗有助于非危重症住院患者实现理想的血糖控制。
J Diabetes Investig. 2020 Jan;11(1):125-131. doi: 10.1111/jdi.13093. Epub 2019 Jun 28.
Zotero 插件